Literature DB >> 27862591

Patient experiences of acute myeloid leukemia: A qualitative study about diagnosis, illness understanding, and treatment decision-making.

Thomas W LeBlanc1,2, Laura J Fish1, Catherine T Bloom3, Areej El-Jawahri4, Debra M Davis1, Susan C Locke1, Karen E Steinhauser5, Kathryn I Pollak1.   

Abstract

BACKGROUND: Patients with acute myeloid leukemia (AML) face a unique, difficult situation characterized by sudden changes in health, complex information, and pressure to make quick treatment decisions amid sizeable tradeoffs. Yet, little is known about patients' experiences with AML. We used qualitative methods to learn about their experiences with diagnosis and treatment decision-making to identify areas for improvement.
METHODS: We recruited hospitalized patients with AML to participate in semi-structured qualitative interviews about their experiences being diagnosed with AML, receiving information, and making a treatment decision. Interviews were conducted during their hospitalization for induction chemotherapy. We analyzed data by using a constant comparison approach.
RESULTS: Thirty-two patients completed an interview. Four main themes emerged: (a) shock and suddenness, (b) difficulty processing information, (c) poor communication, and (d) uncertainty. Patients frequently described their diagnosis as shocking. They also felt that the amount of information was too great and too difficult to process, which negatively impacted their understanding. Patients frequently described a lack of emotional support from clinicians and described uncertainty about their prognosis, the number and nature of available treatments, and what to expect from treatment.
CONCLUSIONS: Acute myeloid leukemia poses a sudden, emotionally challenging, information-laden situation, where little time is available to make important decisions. This results in difficulty processing information and is sometimes complicated by a lack of emotive communication from clinicians. Results indicate a need for targeted interventions to improve AML patients' understanding of illness and treatment options and to address their traumatic experiences around diagnosis.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  acute myeloid leukemia; cancer; oncology; palliative care; qualitative research; supportive care

Mesh:

Year:  2016        PMID: 27862591     DOI: 10.1002/pon.4309

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  23 in total

Review 1.  Early Palliative Care for Patients with Hematologic Malignancies: Is It Really so Difficult to Achieve?

Authors:  Thomas W LeBlanc; Eric J Roeland; Areej El-Jawahri
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

Review 2.  Understanding patients' values and priorities in selecting cancer treatments: Developing a therapy preference scale.

Authors:  Vijaya Raj Bhatt
Journal:  J Geriatr Oncol       Date:  2018-11-27       Impact factor: 3.599

3.  Age at Diagnosis and Patient Preferences for Treatment Outcomes in AML: A Discrete Choice Experiment to Explore Meaningful Benefits.

Authors:  Daniel R Richardson; Norah L Crossnohere; Jaein Seo; Elihu Estey; Bernadette O'Donoghue; B Douglas Smith; John F P Bridges
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-03-04       Impact factor: 4.254

4.  Decisional involvement and information preferences of patients with hematologic malignancies.

Authors:  Kah Poh Loh; Mazie Tsang; Thomas W LeBlanc; Anthony Back; Paul R Duberstein; Supriya Gupta Mohile; Ronald M Epstein; Heidi D Klepin; Michael W Becker; Areej El-Jawahri; Stephanie J Lee
Journal:  Blood Adv       Date:  2020-11-10

5.  The relationship between emotional well-being and understanding of prognosis in patients with acute myeloid leukemia (AML).

Authors:  Anmol Singh; Susan C Locke; Steven P Wolf; Tara A Albrecht; Jesse D Troy; Heather Derry; Areej El-Jawahri; Thomas W LeBlanc
Journal:  Support Care Cancer       Date:  2021-08-17       Impact factor: 3.603

6.  A novel decision aid for acute myeloid leukemia: a feasibility and preliminary efficacy trial.

Authors:  Jordan D Hildenbrand; Debra M Davis; Areej El-Jawahri; Kris W Herring; Susan C Locke; Kathryn I Pollak; Gregory P Samsa; Karen E Steinhauser; Jesse D Troy; Peter A Ubel; Thomas W Leblanc
Journal:  Support Care Cancer       Date:  2020-11-06       Impact factor: 3.603

7.  The impact of remission status on patients' experiences with acute myeloid leukemia (AML): an exploratory analysis of longitudinal patient-reported outcomes data.

Authors:  Neha Kayastha; Steven P Wolf; Susan C Locke; Gregory P Samsa; Areej El-Jawahri; Thomas W LeBlanc
Journal:  Support Care Cancer       Date:  2017-11-18       Impact factor: 3.603

8.  A Cohort Study of Patient-Reported Outcomes and Healthcare Utilization in Acute Myeloid Leukemia Patients Receiving Active Cancer Therapy in the Last Six Months of Life.

Authors:  Jared R Lowe; Yinxi Yu; Steven Wolf; Greg Samsa; Thomas W LeBlanc
Journal:  J Palliat Med       Date:  2018-01-17       Impact factor: 2.947

9.  Development and validation of the Therapy Preference Scale to understand patients´ systemic cancer treatment preferences.

Authors:  Vijaya Raj Bhatt; Prajwal Dhakal; Christopher S Wichman; Bunny Pozehl
Journal:  Future Oncol       Date:  2020-12-02       Impact factor: 3.404

10.  Patient-hematologist discordance in perceived chance of cure in hematologic malignancies: A multicenter study.

Authors:  Kah Poh Loh; Huiwen Xu; Anthony Back; Paul R Duberstein; Supriya Gupta Mohile; Ronald Epstein; Colin McHugh; Heidi D Klepin; Gregory Abel; Stephanie J Lee; Areej El-Jawahri; Thomas W LeBlanc
Journal:  Cancer       Date:  2019-12-06       Impact factor: 6.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.